Merck Betting Up To $2B On China-Developed Cardio Drug
By Jade Martinez-Pogue · March 25, 2025, 3:23 PM EDT
Pharmaceutical giant Merck & Co. Inc., advised by Gibson Dunn & Crutcher LLP and Covington & Burling LLP, said on Tuesday it has entered into an exclusive license agreement with Cooley...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login